Alzinova AB (publ)
Save
77.93M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
Similar securities
Based on sector and market capitalization
Report issue